logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Cerebrovascular Accident

    Medications for Cerebrovascular Accident

    FiltersReset Filters
    7 results

    • atorvastatin calcium

      (Atorvastatin calcium)
      NIVAGEN PHARMACEUTICALS, INC.
      Usage: Atorvastatin calcium is indicated to reduce the risk of myocardial infarction, stroke, and angina in at-risk adults. It also lowers LDL cholesterol in adults with hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and treats primary dysbetalipoproteinemia and hypertriglyceridemia as an adjunct to diet.

    • cozaar

      (losartan potassium)
      Organon LLC
      Usage: COZAAR® is indicated for treating hypertension in adults and pediatric patients aged 6 and older, reducing cardiovascular risks. It is also used to lower stroke risk in hypertensive patients with left ventricular hypertrophy, and to manage diabetic nephropathy in type 2 diabetes patients with hypertension.

    • lodoco

      (Colchicine Tablets 0.5 mg)
      AGEPHA Pharma USA, LLC
      Usage: LODOCO is indicated for reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular disease risk factors.

    • ramipril

      (Ramipril)
      Rising Pharma Holdings, Inc.
      Usage: Ramipril capsules are indicated for treating hypertension, reducing cardiovascular event risks (myocardial infarction, stroke, death) in high-risk patients aged 55 or older, and managing heart failure following myocardial infarction. They may be used alone or in combination with other therapies to achieve desired outcomes.

    • telmisartan

      (Telmisartan)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Telmisartan tablets are indicated for treating hypertension to lower blood pressure and reduce the risk of cardiovascular events such as strokes and myocardial infarctions. They are also used for reducing cardiovascular risk in patients aged 55 and older who are high-risk and cannot take ACE inhibitors.

    • telmisartan

      (Telmisartan)
      Macleods Pharmaceuticals Limited
      Usage: Telmisartan is indicated for hypertension treatment to lower blood pressure and reduce cardiovascular event risks, including strokes and myocardial infarctions. Additionally, it is used to decrease cardiovascular event risks in high-risk patients over 55 who cannot take ACE inhibitors. It can be combined with other treatments.

    • ticagrelor

      (ticagrelor)
      Solco Healthcare U.S., LLC
      Usage: Ticagrelor is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lowers the risk of stent thrombosis and is used to reduce stroke risk in acute ischemic stroke and high-risk transient ischemic attack patients.